Oppenheimer reduced its rating on Emerson EMR from Outperform to Perform and lowered its price target from $57 to $53.
Oppenheimer commented, "We are downgrading shares of EMR to Perform from Outperform, based on lack of high conviction catalysts to drive multiple expansion, and nearterm risk associated with exposure to capital spending. Initial guidance outlook for msd-hsd EPS growth appears a potentially more opportunistic backdrop for expectations, but does include a combined 17c headwind from pension and overlapping stock compensation plans (partially offset by ~6c favorable from lower restructuring spend, and material restructuring benefits)."
Emerson closed at $48.36 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in